Sandra Pohlman is co-founder and partner of df-mp. She co-heads the firm’s large and diversified biotechnology and pharmaceuticals practice group. A main part of her practice is oppositions and prosecution before the European Patent Office, where she has consistently obtained favorable results for her clients. Ms. Pohlman is an experienced patent litigator and adviser in the life science patent field. She is qualified to practice before the European Patent Office as a legal practitioner, the Unified Patent Court (UPC) and the German courts. Additionally, she is a registered U.S. Patent Attorney.
Sandra Pohlman advises international clients in the field of life science patents, with her particular focus in the areas of molecular biology, immunology, pharmaceutical agents and formulations, DNA/RNA based diagnostics, CRISPR, second medical uses and dosing regimens. A main part of her practice is oppositions and prosecution before the European Patent Office, where she has handled over 100 oppositions and hundreds of patent applications.
She has served as lead counsel in notable opposition cases relating to patents for blockbuster drugs and ground-breaking technologies including, more recently, Tecfidera®, Tysabri®, and attacking and defending CRISPR patents, as well as numerous antibody-related oppositions (adalimumab, herceptin, bevacizumab, pertuzumab, nivolumab, pembrolizumab). Ms. Pohlman handles prosecution in the pharmaceutical and biotechnology fields for more than three decades and can deliver complex portfolio strategies that add value.
Year Joined Firm: 2000
Education/Alumni:
- Biology, University of Vermont, U.S.A
- Jurist Doctor Degree (magna cum laude) from the National Law Center of the George Washington University in Washington, DC, U.S.A
Network Memberships: GRUR, VPP, ECTA, INTA, AIPLA
